Monte Rosa Reports GFORCE-1 Data for MRT-8102

Monte Rosa Therapeutics disclosed results from its GFORCE-1 clinical study, reporting that its first-in-class NEK7 molecular glider degrader, MRT-8102, demonstrated a favorable safety profile and sustained target engagement in patients with elevated cardiovascular risk. The company, which trades under the ticker GLUE, released the data via an 8-K filing on October 1, 2026.

The 8-week, randomized study enrolled 108 subjects with elevated cardiovascular disease risk. Participants were assigned to receive MRT-8102 at doses of 5, 20, or 40 milligrams once daily, or a placebo for four weeks. Monte Rosa stated that the drug achieved robust, sustained, and equal NEK7 degradation across all three dose levels.

Safety results showed no serious adverse events in the study population. The rate of treatment-emergent adverse events was 33% in the MRT-8102 groups compared to 30% in the placebo group. The company noted that there was no increased infection risk associated with the treatment.

Beyond target engagement, the data indicated broad normalization of elevated pathogenic drivers associated with atherosclerotic cardiovascular disease. Monte Rosa reported that levels of IL-1b, HMGB1, Calprotectin, S100A12, SAA, and Fibrinogen were reduced to healthy-volunteer levels at all tested doses. The company said these findings demonstrate activity on plaque and vessel wall biology and thrombogenic factors.

The release highlighted a potential precision medicine approach, noting that carriers of NLRP3 risk alleles showed higher baseline levels of DAMPs. Monte Rosa suggested this indicates elevated pathway activity and potential for favorable responses in this specific genetic subgroup.

The filing includes extensive forward-looking statements regarding the development of MRT-8102 and other pipeline candidates, including MRT-9347 and MRT-2359. Monte Rosa stated that it plans to advance Phase 2 development for MRT-8102 in studies designated as GFORCE-2, GEMINI-1, and GALAXY-1. These upcoming trials are intended to evaluate proof of concept, safety, efficacy, and potential cardiovascular benefit.

The company also referenced its collaborations with Novartis and Roche. Monte Rosa expects Novartis to advance MRT-6160 and other VAV1-directed molecular glider degraders in immune-mediated diseases, including additional Phase 2 study initiations. The filing notes that proposed clinical trial designs remain subject to regulatory review and may change.

Monte Rosa cautioned that early clinical results may not be predictive of final outcomes or future trials. The company stated that pharmacodynamic or biomarker effects observed in GFORCE-1 may not translate into clinical or therapeutic benefit. Recipients are advised not to place undue reliance on forward-looking statements, which speak only as of the date they are made.